leadf
logo-loader
viewHumanigen, Inc.

Humanigen contemplating raising funds by conducting a broadly syndicated rights offering

"We are evaluating conducting a rights offering primarily to raise additional capital to pursue our GM-CSF neutralization strategy"

Cancer cell
Humanigen said it has engaged RHK Capital to gauge feedback and interest for this potential rights offering

Humanigen, Inc. (OTCMKTS:HGEN) has revealed that it is contemplating raising funds by conducting a broadly syndicated rights offering involving issuing a dividend of rights and over-subscription rights to purchase shares of its capital stock.

The clinical-stage biopharmaceutical company said a broadly syndicated rights offering would be a democratization of the public offering process allowing all stockholders of record to participate in the process.

READ: Humanigen Inc finds support for its strategy in treating graft-versus-host disease in medical journal article

In this scenario, stockholders as of the record date would receive a right but not the obligation to purchase Shares during a to-be-determined exercise period.

Stockholders as of the record date would also receive over-subscription rights to purchase additional shares beyond their pro-rata percentage ownership.

Humanigen said it has engaged RHK Capital to gauge feedback and interest for this potential rights offering.

Cameron Durant, Humanigen’s chief executive officer said: "We are evaluating conducting a rights offering primarily to raise additional capital to pursue our GM-CSF neutralization strategy in a clinical collaboration with Kite, a Gilead company.

“If we proceed with this offering to our stockholders, our stockholders will have the first opportunity to purchase additional securities to maintain or increase their current percentage ownership in our company and provide capital to us at what we believe are attractive price levels."

Humanigen is developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms.

The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary anti-human-GM-CSF immunotherapy, which is its lead product candidate.

A clinical collaboration with Kite was recently announced to evaluate the sequential use of lenzilumab with Yescarta, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma.

Contact the author at [email protected]

Quick facts: Humanigen, Inc.

Price: - -

OTCMKTS:HGEN
Market: OTCQB
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Personal Group's Deborah Frost says first half has been 'surprisingly good'

Personal Group Holdings PLC's (LON:PGH) Deborah Frost talks Proactive through its interim results to June 2020. The firm achieved revenue and profit growth in the first half of 2020 despite the impact of the coronavirus (COVID-19) pandemic. Group revenue in the six months rose by 1.3% to...

2 days, 1 hour ago

2 min read